Massachusetts is currently home to 3204 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Boston, Worcester, Springfield and Burlington. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Mineralocorticoid Receptor, Coronary Microvascular Function, and Cardiac Efficiency in Hypertension
NCT05593055
Recruiting
The investigators' goal is to show that in hypertensive men and women with left ventricular hypertrophy (LVH) treatment with a mineralocorticoid receptor (MR) antagonist, versus a thiazide-like diuretic, will improve coronary microvascular function and cardiac efficiency, which will associate with improvements in LV structure and function. The investigators will achieve this through a randomized, controlled, basic experimental study involving humans (BESH).
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
12/11/2024
Locations: Brigham and Women's Hospital, Boston, Massachusetts
Conditions: Hypertension, Left Ventricular Hypertrophy
Register for Updates
ARDS in Children and ECMO Initiation Strategies Impact on Neurodevelopment (ASCEND)
NCT05388708
Recruiting
ASCEND researchers are partnering with families of children who receive extracorporeal membrane oxygenation (ECMO) after a sudden failure of breathing named pediatric acute respiratory distress syndrome (PARDS). ECMO is a life support technology that uses an artificial lung outside of the body to do the lung's work. ASCEND has two objectives. The first objective is to learn more about children's abilities and quality of life among ECMO-supported children in the year after they leave the pediatr... Read More
Gender:
ALL
Ages:
Between 14 days and 20 years
Trial Updated:
12/11/2024
Locations: Boston Children's Hospital, Boston, Massachusetts
Conditions: Acute Respiratory Distress Syndrome, Extracorporeal Membrane Oxygenation
Register for Updates
Genomic Biomarker-Selected Umbrella Neoadjuvant Study for High Risk Localized Prostate Cancer
NCT04812366
Recruiting
The objective of this study is to see if providing an appropriate therapy based on the genomic testing of prostate tumour tissue will result in an improved clinical response. Each participant will be treated with 8 weeks of a luteinizing hormone-releasing hormone agonist (LHRHa) plus apalutamide (APA) while genome sequence characterization is being done. Participants with biopsy specimens deemed unevaluable for genomic testing will remain on LHRHa plus APA for an additional 16 weeks. Participa... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
12/11/2024
Locations: Brigham & Women's Hospital, Boston, Massachusetts
Conditions: Prostate Cancer
Register for Updates
The Effect of Mindfulness on Vascular Inflammation in Stable Coronary Disease
NCT04505865
Recruiting
This study aims to evaluate the effect of 8 weeks of a stress reduction intervention on atherosclerotic plaque inflammation in adults with stable coronary artery disease, as quantified by positron emission tomography (PET) with 18F-fluorodeoxyglucose (FDG) in individuals with increased psychosocial stress.
Gender:
ALL
Ages:
Between 45 years and 65 years
Trial Updated:
12/11/2024
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Atherosclerosis, Stress, Inflammation
Register for Updates
Spastic Paraplegia - Centers of Excellence Research Network
NCT06553976
Recruiting
The Spastic Paraplegia - Centers of Excellence Research Network (SP-CERN) is a collaborative research consortium dedicated to advancing the understanding, diagnosis, and treatment of hereditary spastic paraplegia (HSP) and primary lateral sclerosis (PLS). Aims of the consortium are to a) perform natural history studies of HSP subtypes, b) discover and validate biomarkers and clinician- and patient-reported outcome measures, c) uncover HSP's molecular pathophysiology and develop rational therapeu... Read More
Gender:
ALL
Ages:
All
Trial Updated:
12/10/2024
Locations: Boston Children's Hospital, Boston, Massachusetts
Conditions: Hereditary Spastic Paraplegia, Primary Lateral Sclerosis, SPG4, SPG5A, Spastic Paraplegia 4, Spastic Paraplegia 5A, Early Onset Hereditary Spastic Paraplegia, Neuromuscular Diseases, Spastic Paraplegia, Hereditary
Register for Updates
Hereditary Spastic Paraplegia Genomic Sequencing Initiative (HSPseq)
NCT05354622
Recruiting
The purpose of the HSP Sequencing Initiative is to better understand the role of genetics in hereditary spastic paraplegia (HSP) and related disorders. The HSPs are a group of more than 80 inherited neurological diseases that share the common feature of progressive spasticity. Collectively, the HSPs present the most common cause of inherited spasticity and associated disability, with a combined prevalence of 2-5 cases per 100,000 individuals worldwide. In childhood-onset forms, initial symptoms... Read More
Gender:
ALL
Ages:
Between 1 month and 30 years
Trial Updated:
12/10/2024
Locations: Boston Children's Hospital, Boston, Massachusetts
Conditions: Hereditary Spastic Paraplegia, Neurodegenerative Diseases, Pediatric Disorder, Spasticity, Muscle, Motor Neuron Disease, Movement Disorders
Register for Updates
A Novel Vaccine (EO2463) as Monotherapy and in Combination, for Treatment of Patients With Indolent Non-Hodgkin Lymphoma
NCT04669171
Recruiting
The purpose of this study is to define the recommended Phase 2 Dose, safety, tolerability, immunogenicity, and preliminary efficacy of EO2463 during monotherapy and in combination with lenalidomide and/or rituximab in patients with indolent NHL
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/10/2024
Locations: Dana Farber Cancer Institute, Boston, Massachusetts
Conditions: Follicular Lymphoma, Marginal Zone Lymphoma
Register for Updates
Study Assessing MTD, Safety, Tolerability, PK and Anti-tumor Effects of LNS8801alone and with Pembrolizumab
NCT04130516
Recruiting
This Phase 1/2, first-in-human, open-label, multicenter study follows a 3+3 ascending dose escalation design to determine the MTD/RP2D and to characterize the safety, tolerability, PK, and antitumor effects of LNS8801 alone and in combination with pembrolizumab. The study will include a dose escalation phase, a dose expansion phase, and phase 2A cohorts. Up to 200 patients will be accrued for this study. Up to 15 study sites in the United States will participate in the study.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/10/2024
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Solid Tumor, Adult
Register for Updates
Multicenter Symphony IL-6 Monitoring Sepsis ICU Validation Study
NCT06654895
Recruiting
The primary objective of this study is to validate a pre-defined IL-6 concentration cutoff that predicts 28-day mortality in patients who are admitted or are intended to be admitted to the ICU diagnosed with sepsis or septic shock.
Gender:
ALL
Ages:
22 years and above
Trial Updated:
12/09/2024
Locations: Beth Israel Deaconess Medical Center, Boston, Massachusetts
Conditions: Sepsis, Septic Shock
Register for Updates
Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SPL84 in Patients with Cystic Fibrosis
NCT06429176
Recruiting
The goal of this clinical trial is to learn if drug SPL84 is safe for adult patients with cystic fibrosis (CF). It will also learn if the drug works to treat works to treat CF with a specific mutation. The purpose of this research study is to: * test the safety and effectiveness of multiple doses of the study drug, SPL84 * test how multiple doses of the drug are processed by the body Researchers will compare drug SPL84 to a placebo (a look-alike substance that contains no drug) to see if drug... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/09/2024
Locations: Boston Children'S Hospital, Boston, Massachusetts
Conditions: Cystic Fibrosis
Register for Updates
Niraparib in Tumors Metastatic to the CNS
NCT04992013
Recruiting
This research is being done to see how effective the drug niraparib is against cancer that has metastasized to the central nervous system (CNS). * This research study involves the study drug niraparib.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/09/2024
Locations: Massachusetts General Hospital Cancer Center, Boston, Massachusetts
Conditions: Metastatic Cancer, Central Nervous System Cancer
Register for Updates
Multicenter Evaluation of Near Vision and Outdoor Time in Kids Study
NCT06119243
Recruiting
Currently, optical and pharmacological interventions have been developed to prevent the progression of childhood myopia. However, no myopia control strategy has been shown to have complete efficacy in controlling myopia progression in children. One possible reason is that risk factors contributing to the development of myopia were not controlled in previous clinical studies including time outdoors and near vision behaviour. This study aims to quantify time spent outdoors and near vision behavior... Read More
Gender:
ALL
Ages:
Between 4 years and 14 years
Trial Updated:
12/08/2024
Locations: New England College of Optometry, Boston, Massachusetts
Conditions: Myopia
Register for Updates